Announcement no. 12/2007
To OMX the Nordic Exchange Copenhagen, June 1,
2007
Total share capital and total number of votes in Curalogic A/S
Under section 17(2) of Executive Order no. 226 of 15 March 2007 on the
disclosure requirements of issuers, we hereby announce that, as of today,
Curalogic A/S' share capital totals DKK 18,214,408 divided into 36,428,816
shares of DKK 0.50 corresponding to 36,428,816 voting rights.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for
treatment of house dust mite allergy preparing for clinical trials.
This announcement contains forward-looking statements regarding the company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the company's knowledge, are reasonable at
this time, but may prove to be erroneous in the future.
